Mehran Alizadeh Aghdam

Author

Also Known As

Alizadeh Aghdam, Mehran, M Aghdam, M. Alizadeh Aghdam, Mehdi Rashidi Aghdam, Mehran Alizadeh Aghdam, Mohammad Amin Adili Aghdam

Publications

175

Citations

H-Index

Concepts

All Affiliations

University Medical Center Utrecht Utrecht University Radboud University Medical Center Radboud University Nijmegen Erasmus MC

About

Mehran Alizadeh Aghdam is an author at University Medical Center Utrecht specializing in allergy, allergy medicine, and dermatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	51
2	Allergy	2	2	51
3	Allergy Medicine	2	2	51
4	Dermatology	2	2	51
5	Drug Allergy	1	1	32

Mehran Alizadeh Aghdam

Publications

152

Citations

H-Index

Page 1

	Year	Citations
High-dose omalizumab use in patients with chronic spontaneous urticaria Mehran Alizadeh Aghdam, Fenne van den Broek, Feiko Rijken, The Journal of Allergy and Clinical Immunology In Practice AllergyAllergy MedicineMedicineClinical DermatologyPharmacotherapy	2019	32
Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria Mehran Alizadeh Aghdam, Edward F. Knol, Mignon van den Elzen, Clinical & Experimental Allergy	2020	26
Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients Coco Dekkers, Mehran Alizadeh Aghdam, Marlies de Graaf, Pediatric Allergy and Immunology	2020	22
Effective omalizumab interval prolongation in the treatment of chronic urticaria Mehran Alizadeh Aghdam, Rianne Henriëtte Pieterse, Petra A. Kentie, The Journal of Allergy and Clinical Immunology In Practice AllergyAllergy MedicineClinical DermatologyChronic UrticariaDermatology	2020	19
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation Reineke Soegiharto, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, JAMA Dermatology	2024	16
Systemic and local evidence for complement involvement in chronic spontaneous urticaria Mehran Alizadeh Aghdam, Mignon van den Elzen, Harmieke van Os‐Medendorp, Clinical and Translational Allergy	2021	15
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real‐world data from a large multi‐national UCARE study Reineke Soegiharto, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, Allergy	2024	12
Age and fast initial response predict omalizumab retreatment in chronic urticaria Michelle Meertens, Teddy Luijf, Esmee A.M. van Lindonk, The Journal of Allergy and Clinical Immunology In Practice	2023	10

Page 1